BMYBristol-Myers SquibbRunning, no new patients
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Acute Myeloid Leukemia
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2
- Patients
- 19 (final count)
- Started
- Jan 17, 2022
- Main results expected
- Jan 27, 2025
- Fully finished
- Apr 30, 2026
- Results posted
- Feb 11, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence Free Survival (RFS)
Measured over: Approximately 17.7 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05197426 · record last updated 2026-02-11 · checked 2026-11-09 15:47 UTC